0001493152-20-013378.txt : 20200715
0001493152-20-013378.hdr.sgml : 20200715
20200715181309
ACCESSION NUMBER: 0001493152-20-013378
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200713
FILED AS OF DATE: 20200715
DATE AS OF CHANGE: 20200715
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Margolis Jeff Eliot
CENTRAL INDEX KEY: 0001573202
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16467
FILM NUMBER: 201030326
MAIL ADDRESS:
STREET 1: C/O AURORA CAPITAL LLC
STREET 2: 17 PARK AVENUE, #201
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RespireRx Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0000849636
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330303583
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 126 VALLEY ROAD
STREET 2: SUITE C
CITY: GLEN ROCK
STATE: NJ
ZIP: 07452
BUSINESS PHONE: (201) 444-4947
MAIL ADDRESS:
STREET 1: 126 VALLEY ROAD
STREET 2: SUITE C
CITY: GLEN ROCK
STATE: NJ
ZIP: 07452
FORMER COMPANY:
FORMER CONFORMED NAME: CORTEX PHARMACEUTICALS INC/DE/
DATE OF NAME CHANGE: 19920703
4
1
ownership.xml
X0306
4
2020-07-13
0
0000849636
RespireRx Pharmaceuticals Inc.
RSPI
0001573202
Margolis Jeff Eliot
C/O RESPIRERX PHARMACEUTICALS INC.
126 VALLEY ROAD, SUITE C
GLEN ROCK
NJ
07452
1
1
1
0
SVP, CFO, Secret'y & Treasurer
Series H Preferred Stock
0.0064
2020-07-13
4
J
0
500
A
2020-07-13
2023-09-30
Conversion Units
78125000
500
D
Series H Preferred Stock
0.0064
2020-07-13
4
G
0
450
0
D
2020-07-13
2023-09-30
Conversion Units
70312500
50
D
Series H Preferred Stock
0.0064
2020-07-13
4
G
0
450
0
A
2020-07-13
2023-09-30
Conversion Units
70312500
450
I
By Trust
Series H Preferred Stock
0.0064
2020-07-13
4
G
0
25
0
D
2020-07-13
2023-09-30
Conversion Units
3906250
25
D
Series H Preferred Stock
0.0064
2020-07-13
4
G
0
25
0
A
2020-07-13
2023-09-30
Conversion Units
3906250
25
I
By Trust
Series H Preferred Stock
0.0064
2020-07-13
4
G
0
25
0
D
2020-07-13
2023-09-30
Conversion Units
3906250
0
D
Series H Preferred Stock
0.0064
2020-07-13
4
G
0
25
0
A
2020-07-13
2023-09-30
Conversion Units
3906250
25
I
By Trust
The full designation of this class of preferred stock is "Series H 2% Voting, Non-Participating, Convertible Preferred Stock."
On July 13, 2020, Mr. Margolis agreed to forgive a portion of the accrued but unpaid compensation to which he was entitled pursuant to his employment agreement with RespireRx Pharmaceuticals Inc. (the "Company") equal to $500,000. On July 13, 2020, the Company issued to Mr. Margolis 500 shares of the Company's Series H 2% Voting, Non-Participating, Convertible Preferred Stock in exchange for the forgiveness of $500,000 of accrued and unpaid compensation, which equates to a per share value of $1,000.00 per share.
Each Conversion Unit consists of one share of the common stock of the Company, and one warrant exercisable into one share of the common stock of the Company (such warrant having an initial exercise price of $0.007 per share, and terminating on September 30, 2023).
These dispositions and acquisitions reflect estate planning transactions. These securities are being contributed to trusts for the benefit of Mr. Margolis' spouse and children, as specified.
Mr. Margolis gifted these securities into a family trust for the benefit of Mr. Margolis's spouse. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
Mr. Margolis gifted these securities into a family trust for the benefit of his son. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
Mr. Margolis gifted these securities into a family trust for the benefit of his daughter. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
/s/ Jeff Eliot Margolis
2020-07-15